Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1894-6. doi: 10.1016/j.cgh.2014.06.011. Epub 2014 Jun 19.

Authors

Niels Vande Casteele¹, William J Sandborn²

Affiliations

¹ Division of Gastroenterology, University of California San Diego, La Jolla, California; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Leuven, Belgium; Robarts Clinical Trials, Western University, London, Ontario, Canada.
² Division of Gastroenterology, University of California San Diego, La Jolla, California; Robarts Clinical Trials, Western University, London, Ontario, Canada.

PMID: 24951843
DOI: 10.1016/j.cgh.2014.06.011

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
Colitis, Ulcerative / drug therapy*
Feces / chemistry*
Humans
Leukocyte L1 Antigen Complex / analysis*
Male
Mesalamine / administration & dosage*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Leukocyte L1 Antigen Complex
Mesalamine